ArticleOncogene2020

Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.

Francesca Ricciardiello et al.PubMed ↗Publisher ↗

No numbers read from the abstract.